Physiologically based pharmacokinetic modeling for umbelliferone in rats and humans: impact of extrahepatic phase II metabolism and hepatic/gut first-pass extraction on oral bioavailability and systemic disposition
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q1Scopus Q1KCI Q1
- 저널
- Journal of Pharmaceutical Investigation56(1) · pp.185 · 2026
- 피인용
- Web of Science 1Scopus 0KCI 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 5.1
- ISSN
- 2093-5552
저자
- 공지수제1저자Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- 서성욱Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- 김태영Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- 문형룡Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- 유진욱Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- 김민수Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- 윤화영Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- 황성환Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- Hwang, Ee TaekDong A Univ, Dept Food Biotechnol, Busan 49315, South Korea
- 정연진교신저자Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
- 윤인수교신저자Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
초록
PurposeUmbelliferone, one of the most widely distributed coumarins, has beneficial effects in the management of asthma, cardiovascular diseases, diabetes, hepatic/renal injury, and rheumatoid arthritis. This study aimed to quantitatively investigate extrahepatic phase II metabolism and hepatic/gut first-pass effects of umbelliferone using rat and human physiologically based pharmacokinetic (PBPK) models.MethodsIn vitro, in situ, and in vivo experimental data regarding biorelevant stability, protein binding, blood distribution, phase II tissue metabolism (glucuronidation and sulfation), intestinal permeability, and in vivo pharmacokinetics were obtained. Using these datasets, we developed rat and human PBPK models incorporating extrahepatic phase II metabolism and route-dependent gut extraction was developed.ResultsThe rat PBPK model simulations aligned with the observed systemic exposure of intravenously and orally administered umbelliferone with an acceptable prediction accuracy of 0.964-1.29-fold errors. Moreover, human PBPK model simulations suggested that umbelliferone administered orally at doses of 100 and 500 mg exhibited linear pharmacokinetic profiles with peak blood concentrations of 55.0 and 275 ng/mL, respectively, and an oral bioavailability of 9.49% in clinical settings.ConclusionThe PBPK model can be used to predict clinical drug interactions with natural products containing umbelliferone. Furthermore, this study provides an alternative in silico tool to support decision-making during the development of phytochemical-based functional foods when significant phase II metabolism in the liver and other organs is anticipated.
키워드
UmbelliferonePhysiologically based pharmacokinetic modelPhase II extrahepatic metabolismGut first-pass effectsANTIINFLAMMATORY ACTIVITIESGLUCURONIDATIONABSORPTIONCOUMARIN
식별자
- Scopus EID
- 2-s2.0-105015769590
- WoS UID
- 001568712800001
- KCI
- ART003298054



로그인
연구물 목록으로